WO2009151346A1 - Procédé de détermination d'une résistance aux antibiotiques bactériens ou d'une sensibilité bactérienne, coffret de diagnostic pour la détection de la résistance aux antibiotiques et utilisation d'un tel coffret de diagnostic - Google Patents

Procédé de détermination d'une résistance aux antibiotiques bactériens ou d'une sensibilité bactérienne, coffret de diagnostic pour la détection de la résistance aux antibiotiques et utilisation d'un tel coffret de diagnostic Download PDF

Info

Publication number
WO2009151346A1
WO2009151346A1 PCT/PL2009/000066 PL2009000066W WO2009151346A1 WO 2009151346 A1 WO2009151346 A1 WO 2009151346A1 PL 2009000066 W PL2009000066 W PL 2009000066W WO 2009151346 A1 WO2009151346 A1 WO 2009151346A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibiotic
detection
antibiotic resistance
test
resistance
Prior art date
Application number
PCT/PL2009/000066
Other languages
English (en)
Inventor
Marek Ciesielski
Original Assignee
Marek Ciesielski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marek Ciesielski filed Critical Marek Ciesielski
Publication of WO2009151346A1 publication Critical patent/WO2009151346A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9446—Antibacterials

Definitions

  • a method for determining bacterial antibiotic resistance or bacterial susceptibility a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit
  • the subjects of invention are method for determining bacterial antibiotic resistance or bacterial susceptibility, a diagnostic kit for the detection of the antibiotic resistance and use of such diagnostic kit. Mote precisely a new, fast and efficient method for determining the antibiotic resistance of bacteria, screen test for antibiotic-resistant bacteria and test for the efficiency of the antimicrobial treatment, diagnostic set and use to the measurement of the drug detection or their metabolites are described. A new method for detection of bacterial antibiotic resistance, diagnostic set based on the lateral flow test or lateral immunochromatographic assays to detect drug resistance of the contagious factor and use of detection of the drug and/or products of its/theirs degradations are disclosed.
  • Bacterial drug resistance may be detected in different ways. These methods can be divided into techniques used in cell/bacterial culture, e.g. disk diffusion method, colorimetric methods and non-culture techniques among them the most important are genetic techniques, e.g. PCR which enables the detection of DNA/RNA responsible for coding enzyme or based on bio-sensors. Other used methods are techniques based on the immunological techniques, based on the detection of presence special proteins or beta-lactamase enzyme, e.g. immunoblot reaction, slide agglutination test, latex agglutination etc.
  • the lateral flow test or lateral immunochromatographic assays are commonly used diagnostic methods used to detect different compounds in body fluids such as serum or urine, or in the supernatant from the tissue culture or different homogenates.
  • the existing penicillin detection test e.g. Penicillin Rapid Inspection Test from Nankai biotech company is used to detect the food products penicillin spoilage, but not for the detection of the antibiotic resistance, neither screening tests for antibiotic- resistant bacteria, nor for tests for the efficiency of the antimicrobial treatment. Furthermore they are able to detect only a few antibiotics.
  • Patent application No. 2007231923 (pub. 2007-10-04) describes sampling and testing device for the detection of specific molds, allergens, viruses, bacteria, fungi, and other protein containing substances.
  • Embodiments of the device include a sampling member slideably engaged with a base that contains a lateral flow strip adapted to detect specific analytes of interest.
  • the sampling member defines a solvent reservoir that stores an elution solvent in a fluid-tight manner before the device is used to sample and test environmental surfaces.
  • the elution solvent stored in the reservoir is automatically released to a wick assembly of the sampling member.
  • the wick assembly includes a wick adapted to receive, distribute, and retain the elution solvent.
  • the bacteria detection device is a microarray type of device in which an oligonucleotide, which is based on a nucleotide sequence specific to a genus or species to which a target spore-forming, aerobic bacteria belongs, is immobilized on a substrate. Spore-forming, aerobic bacteria present in a test sample can be easily, rapidly and accurately detected and identified based on the presence or absence of successful hybridization between a probe prepared from the test sample and the oligonucleotide immobilized on the substrate.
  • Patent application 2006078951 (publ. 2006-04-13) describes monoclonal antibody binding specifically to the p60 protein of Listeria monocytogenes, a hybridoma cell producing the monoclonal antibody, a test kit comprising the monoclonal antibody, and a method for detecting Listeria monocytogenes using the monoclonal antibody.
  • the inventive monoclonal selectively recognizes only Listeria monocytogenes, so that the use of such an antibody allows for rapid determination of the food contamination with these bacteria pathogenic to humans.
  • Patent application 2005272113 (publ. 2005-12-08) describes a reagent for the detection of an extracellular enzymatically active protein produced by a beta-hemolytic streptococcus bacteria found in a host biological fluid includes a proteinaceous substrate or a cholesterol-containing membrane substrate for the extracellular protein.
  • the substrate is nonspecific within the groups of beta-hemolytic streptococcus bacterium and is in contact with an inert solid matrix.
  • Extracellular streptococcus protein found in saliva represents a less invasive source of biological fluid for the determination as to whether a host suffers acute pharyngitis.
  • Patent application WO03107007 (publ. 2003-12-24) describes rapid a test method for detecting at least one antigen by means of optical and/or chemical detection, using specific interactions.
  • the inventive method is a universal rapid test method, which enables bacteria and viruses to be simultaneously and quantitatively determined.
  • Patent description PL 195495 discloses a process for determination of the presence and/or amount of antibiotics containing beta-lactam ring present in a biological fluid and especially in milk.
  • the process complexes the antibiotic in the biological fluid with a known amount of recognition agent and then places the mixture of the biological fluid and recognition agent in contact with an antibiotic a support. A determination is made of the amount of the antibiotic present in the biological fluid.
  • recognition factor is used BIaR receptor or the BIaR-CTD receptor.
  • Patent description No. 6 485 982 describes "including determination of the presence of metabolites of drugs or toxins.
  • the assay process and the cell are engineered specifically to detect the presence of a preselected individual ligand present in a body or other fluids.”
  • evaluation antibiotic resistance are useful, but expensive and time-consuming. They also require highly qualified staff. According to these disadvantages, there is still a need to develop an antibiotic resistance test and method that could guarantee sensitivity, reliability and should be achieved in a fast, easy, and cheap manner.
  • the main aim of this invention is to deliver a method, which could confirm the lack of antibiotic or its presence in concentration, lower than therapeutic concentration, based on the immunoenzymatic detection of medications or the lack of their presence.
  • the applicant has just discovered a novel process for detecting antibiotic resistance, screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment by evaluation of presence of antibiotics in a biological fluid, which allows these objectives to be achieved in a noteworthy manner.
  • the invention discloses a process of detection of antibiotic resistance or a screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment, which is characterised that antibiotic resistance is detected by the lack of given antibiotic in the body fluids, because the antibiotic resistant bacteria destroy/degrade the antibiotic (to the inactive compounds).
  • the presence (or absence) of an antibiotic is detected by the lateral flow test or lateral immunochromatographic assays.
  • the subject of invention is a method for determining bacterial antibiotic resistance or bacterial susceptibility, characterised in that, the drug resistance is detected by detection of the given antibiotic in the urine or other body fluids with the diagnostic set based on the lateral flow test or lateral immunochromatographic assays.
  • said antibiotic resistance is detected when concentration of a given antibiotic or its active metabolites is lower or equal than therapeutic concentration.
  • said antibiotic susceptibility is detected when concentration of a given antibiotic or its active metabolites is higher or equal to therapeutic concentration.
  • said method concerns human and/or animal organisms.
  • said method could be used as screening method of healthy organisms, which could be asymptomatic carriers of antibiotic resistant bacteria.
  • the next subject of invention is a diagnostic kit based on the lateral flow test or lateral immunochromatographic assays for the detection of the antibiotic resistance of the infective factor characterised in that said kit is a diagnostic assay contains a set of antibodies, preferably monoclonal antibodies, for detection of antibiotic resistance by detection of the presence of lack of the given antibiotic wherein said antibiotics are betalactams in biological fluids, especially in urine.
  • said set is useful for screening healthy organisms or monitoring treatment efficiency.
  • the next subject of invention is an use of a diagnostic kit for detection of drug presence and/or its active metabolites by detection of its concentration in comparison to the therapeutic concentration in the body fluids with the lateral flow test or lateral immunochromatographic assays in screening and treatment of patients during antibiotic therapy to the antibiotic resistance detection in screening of the antibiotic resistance of the given antibiotic.
  • antibiotic resistance is stated when concentration of a drug or/and its active metabolites is lower or equal than its therapeutic concentration.
  • antibiotic susceptibility is, stated when concentration of a drug or/and its active metabolites are higher or equal to its therapeutic concentration.
  • said use concerns human and/or animal organisms.
  • it concerns screening of healthy organisms, which could be asymptomatic carriers of antibiotic resistant bacteria.
  • Figure 1 illustrates, for better understanding, the test for detection of antibiotic resistance (or screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment), wherein: 1 - input window, 2 - result window, 3 - test window, 4 - printed, 5 - urine or other body fluids, 6 - mobile Ab#l , 7 - bound Ab#2, 8 - bound Ab#3.
  • Example Test - diagnostic set - is based on the lateral flow test or lateral immunochromatographic assays for detection of the drug resistance of infective factors, which is characterised, that drug resistance (e.g. antibiotic resistance) of the infective factor/s (e.g. bacteria which cause infection) comprise diagnostic set containing set of antibodies (e.g. monoclonal antibodies) to the antibiotic resistance detection by detection presence or absence of administered drug, and especially beta-lactam antibiotics (list below) in the biological fluids and especially in the urine.
  • the above test may be used as a screen test for antibiotic resistance and efficient method of controlling the efficiency of antibiotic treatment as well.
  • patient may be resistant to given beta-lactam antibiotic (e.g. amoxicillin), but it is still administered (with other antibacterial drugs), when the infectious factor is eliminated from the organism the amoxicillin might be detected in the urine again.
  • beta-lactam antibiotic e.g. amoxicillin
  • antibiotics which can be detected by means of the processes according to the present invention, mention may be made of the following antibiotics: Ampicillin, Pivampicillin, Carbenicillin, Amoxicillin, Carindacillin, Bacampicillin, Epicillin, Pivmecillinam, Azlocillin, Mezlocillin, Mecillinam, Piperacillin, Ticarcillin, Metampicillin, Talampicillin, Sulbenicillin, Temocillin, Hetacillin, Benzylpenicillin, Phenoxymethylpenicillin, Propicillin, Azidocillin, Pheneticillin, Penamecillin, Clometocillin, Benzathine benzylpenicillin, Procaine benzylpenicillin, Benzathine phenoxymethylpenicillin, Dicloxacillin, Cloxacillin, Methicillin, Oxacillin, Flucloxacillin, Sultamicillin, Cefalexin, Cefaloridine, Cefalotin, Cefa
  • the lateral flow test (lateral immunochromatographic assays) is a very sensitive method of detection of medication present in urine comparing to HPLC (high performance liquid chromatography). Table 4
  • the lateral flow test (lateral immunochromatographic assays) to HPLC (high performance liquid chromatography) for all the beta-lactam antibiotics.
  • the lateral flow test (lateral immunochromatographic assays) specificity and sensitivity is 99.99%. Presented is monitoring efficiency of elimination of beta-lactams producing bacteria, when they are absent the penicillins started to be present in urine.
  • Bacteria MRSA Metal-resisitant Staphylococcus aureus
  • Bacteria MRSA are resistant to all known beta-lactams antibiotics, and in 90% there is a cross-resistance with macrolides and fluorochinolones.
  • This can mean resistance to such macrolides as: erythromycin, spiramycin, roxythromycin, clarithromycin, azythromycin, telithromycin, and such fluorochinolones as ofloxacyllin, ciprofloxacillin, pefloxacyllin, norfloxacillin, levofloxacillin, moxyfloxacillin. So the proposed test is also useful in detection (with 90% probability) resistance to these antibiotics.
  • Resistance to aminoglicosides is caused by synthesis of the enzyme, which modifies the drug, which is localised on the transposon Tn-4001. So proposed test is also useful to detect resistance to aminoglicosides antibiotics (streptomycin, tobramycin, gentamycin, neomycine, amikacine, netelmycine etc.).
  • Proposed diagnostic test may be also very useful in the veterinary and other biological sciences. It may let to discover new mechanisms of drug resistance e.g. presence of endogenic enzymes of drug degradation.
  • the lateral flow test (lateral immunochromatographic assays) is cheap, sensitive, efficient, easy to operate device, which (thanks to above mentioned features) may be a useful tool to achieve further progress in medicine, veterinary and other biological sciences.
  • the greatest advantage of the proposed lateral flow test is the immediate response for the most important question (from the point of view patient and his/her doctor): is the used treatment effective or not?
  • the threshold sensitivity depends on the local epidemiological date and the type of an antibiotic and is compared between 1-999 micrograms/ml. Below this border (1-999 micrograms/ml) the result is recognised as negative, i.e. the antibiotic level is below this antibiotic concentration it means that the bacteria (responsible for infection or co- infection) are resistant to administered antibiotic.
  • the positive result i.e. detection of antibiotic in urine
  • penicillinase or similar enzyme which degrade the antibiotic
  • Test consists of a box with three windows: the first one - administration of a urine (or other body fluids), the second one - a result window, and the third one - a control window.
  • a wick from a material (e.g. paper) which is easy to moisten by the biological fluids.
  • On the "wick” there are: a) mobile primary antibody Ab#l (e.g. monoclonal antibody) - recognition agent against given antibiotic (or its active metabolite); b) secondary antibody Ab#2 (e.g. monoclonal antibody) which connects to the other epitop of the given antibiotic.
  • the secondary antibody is coupled with to a labelling agent. This labelling agent can be of diverse nature.
  • the labelling agent can be of particular type such as metallic colloidal particles (platinum, gold, silver, etc.), colloidal particles of selenium, carbon, sulphur or tellurium, or alternatively colloidal particles of coloured synthetic latexes.
  • the labelling agent can also be a fluorescent substance, the labelling agent can also be enzymatic
  • the fluid fraction along with its dissolved components including given antibiotic moves along with the liquid front.
  • control window shows plus to indicate that the antibodies in the paper (or the other spongy substance) were alright and working. This is to ensure the patient that the device had not become overheated (or damaged in any other way) during transit. If it had, patient would have two minuses - the second one telling the patient to take the device back because it could be a false negative.
  • the urine (or other body fluid) is applied.
  • the test result is "minus-plus.” It is also possible to detect antibiotic resistance by analysis of patient's body fluids. When antibiotic's concentration is higher or equals to the minimal inhibitory concentration in the body fluids, the bacteria is susceptible to the given antibiotic. In case when antibiotic's concentration is lower than the minimal inhibitory concentration in the body fluids the infectious factor is resistant to the given antibiotic. It could be done by redox reaction with iron chloride.
  • the beta-lactam antibiotics are detected by hydrolysis of present antibiotic in the urine to the hydroxam acids (e.g. hydroxylamin) and FeCl 3 is added. In case of presence of beta-lactams (lack of antibiotic resistance) the violet colour appears.
  • the antibiotic presence detection of antibiotic resistance or susceptibility
  • the process according to the invention allow the detection of antibiotics resistance in biological fluids such as urine, saliva, milk, blood, serum saliva, culture media, pus, wound discharge etc.
  • biological fluids such as urine, saliva, milk, blood, serum saliva, culture media, pus, wound discharge etc.
  • Amoxicillin is a beta-lactam antibiotic, which is active against Gram-positive and Gram-negative organisms but is inactivated by penicillinases, including those produced by Staphylococcus aureus and by common Gram-negative bacilli such as Escherichia coli. Amoxicillin is recommended as "first - line" antibiotic in most infections.
  • microbiological result was known - Staphylococcus epidermidis, amoxicillin susceptible, the microbiological culture result confirmed the lateral flow test.
  • Phenoxymethylpenicillin is an oral beta-lactam antibiotic. Its antibacterial spectrum compares Streptococcus spp. and Staphylococcus spp. (which do not produce penicillinases). Phenoxymethylpenicillin (Penicillin V) is recommended as "first - line" antibiotic in most throat infections. Two patients, A and B complained of a usual bacterial throat infection. They were admitted by their General Practitioner who prescribed them a standardise of 500 mg four times a day. The General Practitioner recommended also an antibiotic resistance lateral flow test to be done 6 hours after first dose of an antibiotic. He took also a standard bacteriological swab.
  • Patient A did a test and the result was positive (it showed that antibiotic is in the urine in concentration higher than therapeutic ones) so the treatment was continued.
  • Patient B did a test as well and the result was negative (it showed that antibiotic is in the urine in concentration lower than therapeutic or was absent).
  • the treatment was changed into amoxicillin with clavulanic acid (in standard doses). Six hours after administration of the antibiotics another test was carried out, which showed susceptibility on the given treatment.
  • Cefalexin is a "first generation" of cefalosporins - broad-spectrum antibiotics that are used in the treatment septicaemia, pneumonia, meningitis, urinary tract infections etc.
  • the pharmacology of the cefalosporins is similar to that of the penicillins, excretion being principal renal.
  • Pregnant patient (30-gestation week) complains of symptoms of lower urinary tract bacterial infection.
  • Cefuroxime is a "second generation " cephalosporin that is less susceptible than the earlier cephalosporins to inactivation by beta-lactamases (except extended spectrum beta-lactamases). It is, therefore, active against certain bacteria, which are resistant to the other drugs, and has greater activity against certain bacteria.
  • Sepsis is a serious medical condition characterised by a whole-body inflammatory state caused by infection. Sepsis is broadly defined as the presence of various pus-forming and other pathogenic organisms, or their toxins, in the blood or tissues. Sepsis is common and also more dangerous in elderly, immunocompromised, and critically ill patients.
  • ICU intensive care unit
  • a common antibiotic regimen in infants with suspected sepsis is a beta-lactam antibiotic (usually ampicillin) in combination with an aminoglycoside (usually gentamicin) or a third-generation cephalosporin (usually cefotaxime — ceftriaxone is generally avoided in neonates due to the theoretical risk of causing biliary stasis.)
  • the organisms which are targeted are species that predominate in the female genitourinary tract and to which neonates are especially vulnerable to, specifically Group B Streptococcus, Escherichia coli, and Listeria monocytogenes (This is the main rationale for using ampicillin versus other beta-lactams.)
  • neonates are also vulnerable to other common pathogens that can cause meningitis and bacteremia such as Streptococcus pneumoniae and Neisseria meningitidis.
  • anaerobic species are suspected (such as in cases where necrot)
  • the identification of the causative pathogen in sepsis can provide useful information to the doctor. In the past, this has been accomplished by growing bacterial cultures. However, this is a slow process as it takes a few days to grow up the cultures and correctly identify the pathogens.
  • New molecular diagnostic tests e.g. Roche's SeptiFast and SIRS Labs' Vyoo
  • Roche's SeptiFast and SIRS Labs' Vyoo are now available that uses genetic material from the pathogen to quickly (within hours) provide results.
  • current practice has been to skip these tests altogether and directly prescribe broad-spectrum antibiotics to the patient.
  • the proposed test has a greater advantage over so far proposed tests. An 8 year old child was admitted to hospital with sepsis. The sample of blood was taken for bacteriological test (culture and antibiotic resistance).
  • the hospital does not have a molecular laboratory.
  • the standard antibiotic treatment with IV cefuroxime was introduced. After 70 min since antibiotic administration it was possible to obtain the first urine sample (in case of emergency when urine is not accessible it is possible to use blood serum or even saliva). The result was "probably positive", and because of the direct life threatening the test was repeated after 3 and 6 hrs of the first administration of an antibiotic, to confirm the result and monitor the efficiency of treatment as well.
  • the above case is an example that results obtained in proposed tests are faster than all tests used so far, is simpler and cheaper.
  • the above test enables to detect antibiotic resistance even in case of an unknown mechanism.
  • Treatment monitoring/supervision A very important feature of the proposed antibiotic resistance diagnostic set based on the lateral flow test or lateral immunochromatographic assays is using it as a test for the efficiency of antibacterial treatment. It can be described by below example.
  • Screening examination is aimed to detect asymptomatic carries of potentially pathogenic microorganisms, which produce penicillinase.
  • the screening is extremely important in case of persons who are exposed on occupational injuries (e.g. firemen) - in case of broken bones the wound could be settled by pathogenic microorganisms, which could be very difficult to eradicate.
  • the screening has an importance for patients who have artificial implants (e.g. artificial heart valves, etc.) because there is a risk of serious complications in case of colonisation by pathogenic organisms.
  • the screening is very useful for patients who have to take the antibiotics as prevention against infection (e.g. in case of cystic fibrosis, after splenectomy, after tick bit - to prevent Lyme disease etc.), in such case early detection of beta-lactamase producing bacteria helps to change ineffective antibiotic prevention.
  • test test patient takes a standard dose of 250 mg of amoxicillin and after 6 hrs a few drops of urine is put on the lateral flow test (or lateral immunochromatographic assays). In case of positive results (when the antibiotic is detected in urine) there is a proof of proper treatment, in case of negative result (when antibiotic is not detectable) the further examination should be done to find a source of potential infection.
  • lateral flow test or lateral immunochromatographic assays
  • Mastitis is the inflammation of the mammary gland. Mastitis is the most common and the most expensive disease of the cows. This disease and resulting infection can significantly reduce the amount and quality milk production. Mastitis is most commonly found in dairy herds. It is now recognised as a growing problem in beef herds, too. This is a growing problem in beef herds, and can result in weaning weights being reduced by 7% to 12.5%. The cost of one case of mastitis is about 370 €. Different types of mastitis could concern from 30-80 % of the herd. Two types of mastitis (infectious and non-infectious) can occur. The vast majority (99%) of the cases is infectious.
  • streptococci ⁇ Streptococcus agalactiae, Streptococcus dysgalactiae i Streptococcus uteris), staphylococci (e.g. Staphylococcus aureus and others,), and E. coli.
  • Antibiotics are the main group of medications which are use in the treatment and prevention of mastitis. The efficiency of treatment is constanty decreasing (even new antibiotic generations are enter into treatment). The most important reason is that bacteria acquire resistance to widely used antibiotics.
  • the veterinary guidelines recommend the bacterial culture with susceptibility (disk diffusion method) before treatment. Otherwise the treatment could be ineffective and a farmer would lose money because of long treatment and decreased milk production.
  • Diagnosed mastitis was commenced with standard cloxacillin suspension, which was administered to an udder (500mg/10g). The drug was administered after udders' were disinfected with careful milking of the infected udder. During the next milking the milk sample was taken, the presence of antibiotic was detected what means the infectious factor is susceptible on administered antibiotic, and the therapy may be continued during the next three days in 24hrs intervals (to prevent recurrence of the disease). In case of negative result the antibiotic would have to be changed. The usage of the new lateral flow test or lateral immunochromatographic assays to detect antibiotic resistance let to decreasing the cost, the given result is faster and lead to the short the pain of the animal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur un procédé de détermination d'une résistance aux antibiotiques bactériens ou d'une sensibilité bactérienne, sur un coffret de diagnostic pour la détection de la résistance aux antibiotiques et sur l'utilisation d'un tel coffret de diagnostic. Plus précisément, l'invention porte sur un nouveau procédé rapide et efficace de détermination de la résistance aux antibiotiques bactériens, sur un test de criblage pour des bactéries résistantes aux antibiotiques et sur un test pour l'efficacité du traitement antimicrobien, sur un ensemble diagnostic et sur l'utilisation pour la mesure de la détection de médicaments ou de leurs métabolites. L'invention porte aussi sur un nouveau procédé pour la détection d'une résistance aux antibiotiques bactériens, sur un ensemble diagnostic basé sur le test d'écoulement latéral ou des essais immunochromatographiques latéraux pour détecter une résistance à un médicament du facteur contagieux et sur l'utilisation de la détection du médicament et/ou de produits de sa/leurs dégradations.
PCT/PL2009/000066 2008-06-11 2009-06-10 Procédé de détermination d'une résistance aux antibiotiques bactériens ou d'une sensibilité bactérienne, coffret de diagnostic pour la détection de la résistance aux antibiotiques et utilisation d'un tel coffret de diagnostic WO2009151346A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLPL385415 2008-06-11
PL385415A PL385415A1 (pl) 2008-06-11 2008-06-11 Sposób wykrywania bakteriooporności, zestaw diagnostyczny oraz zastosowanie oznaczania obecności leku i/lub produktów jego rozpadu

Publications (1)

Publication Number Publication Date
WO2009151346A1 true WO2009151346A1 (fr) 2009-12-17

Family

ID=39718147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2009/000066 WO2009151346A1 (fr) 2008-06-11 2009-06-10 Procédé de détermination d'une résistance aux antibiotiques bactériens ou d'une sensibilité bactérienne, coffret de diagnostic pour la détection de la résistance aux antibiotiques et utilisation d'un tel coffret de diagnostic

Country Status (3)

Country Link
GB (1) GB2460882A (fr)
PL (1) PL385415A1 (fr)
WO (1) WO2009151346A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102253216A (zh) * 2011-03-10 2011-11-23 北京维德维康生物技术有限公司 一种基于青霉素结合蛋白的检测β-内酰胺类抗生素的方法及专用试剂盒和试纸条
CN103645273A (zh) * 2013-12-12 2014-03-19 佟雪梅 β-内酰胺类抗生素耐药性的检测方法、系统及其应用
CN103713133A (zh) * 2012-09-29 2014-04-09 北京勤邦生物技术有限公司 检测螺旋霉素、链霉素、庆大霉素、新霉素的试纸条及方法
WO2018106546A1 (fr) * 2016-12-06 2018-06-14 Silver Lake Research Corporation Procédés de détection de bactéries résistant aux antibiotiques

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597319B2 (en) * 2014-04-23 2017-03-21 Case Western Reserve University Compositions and methods of inhibiting metallo-β-lactamases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103536A (en) * 1997-05-02 2000-08-15 Silver Lake Research Corporation Internally referenced competitive assays
US20020192715A1 (en) * 1998-06-25 2002-12-19 Jacques Degelaen Test kit for determining process for determining antibiotics containing a beta-lactam ring in a biological fluid
CN200982971Y (zh) * 2005-04-15 2007-11-28 华南农业大学 青霉素快速半定量检测试纸

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009692D0 (en) * 1990-04-30 1990-06-20 Ucb Bioproducts An enzymatic method of determining beta-lactam ring antibiotics
EP0593112B1 (fr) * 1992-10-06 1998-08-26 Gist-Brocades N.V. Détection d'antibiotiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103536A (en) * 1997-05-02 2000-08-15 Silver Lake Research Corporation Internally referenced competitive assays
US20020192715A1 (en) * 1998-06-25 2002-12-19 Jacques Degelaen Test kit for determining process for determining antibiotics containing a beta-lactam ring in a biological fluid
CN200982971Y (zh) * 2005-04-15 2007-11-28 华南农业大学 青霉素快速半定量检测试纸

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102253216A (zh) * 2011-03-10 2011-11-23 北京维德维康生物技术有限公司 一种基于青霉素结合蛋白的检测β-内酰胺类抗生素的方法及专用试剂盒和试纸条
CN103713133A (zh) * 2012-09-29 2014-04-09 北京勤邦生物技术有限公司 检测螺旋霉素、链霉素、庆大霉素、新霉素的试纸条及方法
CN103645273A (zh) * 2013-12-12 2014-03-19 佟雪梅 β-内酰胺类抗生素耐药性的检测方法、系统及其应用
CN103645273B (zh) * 2013-12-12 2015-12-30 宁波诺威医疗器械有限公司 β-内酰胺类抗生素耐药性的检测方法、系统及其应用
WO2018106546A1 (fr) * 2016-12-06 2018-06-14 Silver Lake Research Corporation Procédés de détection de bactéries résistant aux antibiotiques

Also Published As

Publication number Publication date
GB2460882A (en) 2009-12-16
PL385415A1 (pl) 2009-12-21
GB0812469D0 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
Bryant et al. β-Lactamase activity in human pus
Bryant et al. Interaction of purulent material with antibiotics used to treat Pseudomonas infections
Alshaalan et al. Brucellosis in children: Prevention, diagnosis and management guidelines for general pediatricians endorsed by the Saudi Pediatric Infectious Diseases Society (SPIDS)
US4992365A (en) Method of detecting bacteria in urine
CN101790683A (zh) 用于诊断微生物感染的组合物和装置
WO2009151346A1 (fr) Procédé de détermination d'une résistance aux antibiotiques bactériens ou d'une sensibilité bactérienne, coffret de diagnostic pour la détection de la résistance aux antibiotiques et utilisation d'un tel coffret de diagnostic
Kuriyama et al. Antimicrobial chemotherapy: Significance to healthcare
Jain et al. Escherichia vulneris: an unusual cause of complicated diarrhoea and sepsis in an infant. A case report and review of literature
Ogata et al. Thoracic empyema caused by Campylobacter rectus
JP5615712B2 (ja) 血液培養サンプルから抗生物質を除去するための方法
Jauregui et al. Cefepime as treatment for osteomyelitis and other severe bacterial infections
Doone et al. Risk factors for penicillin-resistant systemic pneumococcal infections in children
US20140228248A1 (en) Methods and compositions for detecting infections
Barber et al. Antibiotic sensitivity of Proteus species
Abed et al. Relationship between antimicrobial resistance and virulence factors in uropathogenic Escherichia coli isolates from Ramadi, Iraq: phenotype and genotype identification
Isozaki et al. A case of urinary tract infection caused by Kluyvera ascorbata in an infant: case report and review of the literature
Pal et al. Rat Bite Fever: An Infectious Under Reported Bacterial Zoonotic Disease
Boothe Interpreting culture and susceptibility data in critical care: perks and pitfalls
Saleh et al. Biofilm formation and antibiotic susceptibility of uropathogens in patients with catheter associated urinary tract infections in ibb City-Yemen
En et al. Pediatric brain abscess with fatal outcome caused by hypervirulent Klebsiella pneumoniae, serotype K2-ST65
Ito et al. Porphyromonas gingivalis infection in the oral cavity is associated with elevated galactose-deficient IgA1 and increased nephritis severity in IgA nephropathy
Cruz et al. Fatal melioidosis in an oaxacan child
SABAH et al. Immunological parameters examination of the oral fluid in normal and pathological conditions: sensitivity analysis of microorganisms in modern therapeutic practice in vitro
Poindexter et al. Results of noncomparative studies of cefotetan in the treatment of obstetric and gynecologic infections
Alipour et al. Prevalence of CTX-M, OXA and KPC genes in Klebsiella pneumoniae isolates obtained from patients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09762727

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09762727

Country of ref document: EP

Kind code of ref document: A1